Close Menu

NEW YORK (GenomeWeb) – Drug discovery firm Immuneering is teaming with the UK-based Dementia Discovery Fund in an effort to identify new drug targets and candidates for patients with Alzheimer's disease.

The Dementia Discovery Fund, or DDF, said today that it will spend $1.3 million to use Immuneering's drug discovery platform to analyze public data sets on Alzheimer's patients. DDF and Immuneering hope to generate new molecular entities for potential treatment of the neurodegenerative disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.

NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.

The New York Times reports on how environmental DNA sampling could monitor endangered species.

In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.

Mar
18
Sponsored by
Roche

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.